新股消息 | 觅瑞集团更新招股书核心产品已在新加坡成功商业化

智通财经网2025-05-07

智通财经APP获悉，据港交所5月7日披露，觅瑞集团(Mirxes Holding Company Limited)向港交所主板递交上市申请，中金(CICC)、建银国际(CCBI)为其联席保荐人。招股书显示，该公司成立于2014年，是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，致力于使疾病筛查诊断解决方案在亚洲关键市场(包括新加坡及中国)触手可及。截至2025年4月27日，该公司拥有...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533791466?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20250507/20250507160408_72207.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2025-05-07 16:02","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2533791466","market":"sh","top_or_hot":-1,"title":"新股消息 | 觅瑞集团更新招股书 核心产品已在新加坡成功商业化","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，据港交所5月7日披露，觅瑞集团(Mirxes Holding Company  Limited)向港交所主板递交上市申请，中金(CICC)、建银国际(CCBI)为其联席保荐人。招股书显示，该公司成立于2014年，是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，致力于使疾病筛查诊断解决方案在亚洲关键市场(包括新加坡及中国)触手可及。截至2025年4月27日，该公司拥有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1290150.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 觅瑞集团更新招股书 核心产品已在新加坡成功商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 觅瑞集团更新招股书 核心产品已在新加坡成功商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 16:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1290150.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，据港交所5月7日披露，觅瑞集团(Mirxes Holding Company  Limited)向港交所主板递交上市申请，中金(CICC)、建银国际(CCBI)为其联席保荐人。招股书显示，该公司成立于2014年，是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，致力于使疾病筛查诊断解决方案在亚洲关键市场(包括新加坡及中国)触手可及。截至2025年4月27日，该公司拥有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1290150.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242652126.USD","symbol_name":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1290150.html","article_id":"2533791466","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20250507/20250507160408_72207.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533791466","pubTimestamp":1746604947,"columns":[{"name":"新股","id":7,"label_key":null}],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"据港交所5月7日披露，觅瑞集团(Mirxes Holding Company Limited)向港交所主板递交上市申请","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2401740654.USD":"FIDELITY SUSTAINABLE GLOBAL DIVIDEND PLUS \"A\" (USD) INC","LU1920062954.HKD":"FIDELITY FUNDS GLOBAL DIVIDEND PLUS \"A\" (HKDHDG) INC","LU0898667661.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","LU0205439572.USD":"富达亚太股息基金","SG9999001135.SGD":"United ASEAN Fund SGD","LU0192582467.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" (USD) INC MF","SG9999016042.SGD":"Schroder Singapore Trust A Acc SGD","S68.SI":"新加坡交易所","ES3.SI":"STI ETF","STI.SI":"富时新加坡海峡指数","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","BK6033":"金融交易所和数据","FSTAS.SI":"富时海峡全股指数","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","LU0831103253.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","LU0877626530.USD":"FIDELITY ASIA PACIFIC DIVIDEND \"A\" (USD) INC MONTHLY (G)","SG9999001846.SGD":"Schroder Asian Equity Yield A Dis SGD","SGXZ27511609.SGD":"NIKKO AM SINGAPORE DIVIDEND EQUITY \"SGD\" (SGD) ACC","LU1119993845.HKD":"FIDELITY ASIA PACIFIC DIVIDEND \"A\" (HKDHDG) INC","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","LU2242646235.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) ACC","LU0188438112.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" ACC","FSTM.SI":"富时海峡中盘指数","BK6516":"银行与投资服务概念","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999000343.SGD":"Schroder Singapore Trust A Dis SGD","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","02629":"MIRXES-B","BK6523":"ESG概念","LU1920063259.USD":"FIDELITY FUNDS GLOBAL DIVIDEND PLUS \"A\" (USDHDG) INC"},"translate_title":"New Stock News Mirui Group updates its prospectus and core products have been successfully commercialized in Singapore","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ES3.SI":0.6,"STI.SI":1,"FSTM.SI":0.6,"FSTAS.SI":0.6,"S68.SI":1,"02629":1},"content_text":"智通财经APP获悉，据港交所5月7日披露，觅瑞集团(Mirxes Holding Company  Limited)向港交所主板递交上市申请，中金(CICC)、建银国际(CCBI)为其联席保荐人。招股书显示，该公司成立于2014年，是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，致力于使疾病筛查诊断解决方案在亚洲关键市场(包括新加坡及中国)触手可及。截至2025年4月27日，该公司拥有一种核心产品(即GASTROClearTM)、两种其他商业化产品(即LUNGClearTM及FortitudeTM)及六种处于临床前阶段的候选产品。核心产品GASTROClearTM为一个由12种miRNA生物标志物组成的用于胃癌筛查的基于血液的miRNA检测组。GASTROClearTM已于2019年5月获得新加坡卫生科学局(HSA)的C类体外诊断(IVD)证书后在新加坡成功商业化。根据弗若斯特沙利文的资料，该公司是用于癌症及其他疾病早期检测的、有效的、无创的、可负担的、基于血液的miRNA检测试剂盒的提供商。该公司是全球为数不多的已获得分子癌症筛查行业*IVD产品监管批准的公司之一，同时也是全球范围内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。该公司是整体疾病筛查方法市场中液体活检子类别的市场参与者。核心产品GASTROClear™乃癌症检测的筛查方法之一，尤其专注于基于miRNA的液体活检。癌症筛查涉及对有患癌风险的个体进行检测，以便及早发现疾病或预防并发症，而灵敏度及特异性乃衡量检测有效性的关键标准。主要癌症筛查方法包括蛋白质类标志物、影像检测、内窥镜检查及液体活检，液体活检是一种新兴的分子诊断方法，其利用血液或尿液等液体样本检测癌症生物标志物，例如循环肿瘤细胞、ctDNA及miRNA。财务方面，2022年、2023年及2024年，觅瑞集团实现收益分别约为1775.90万美元、2418.50万美元、2028.27万美元，同期毛利约为932.64万美元、1358.2万美元、888.7万美元。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533791466","isCrawlerRequest":true}

新股消息 | 觅瑞集团更新招股书 核心产品已在新加坡成功商业化

精彩评论

新股消息 | 觅瑞集团更新招股书核心产品已在新加坡成功商业化